abstract |
The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF α signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as 'TRAF2 truncated' or 'TRAF2TR' and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as 'TRAF2 truncated-deleted' or 'TRAF2TD'. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF α signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF α binding. |